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Abstract
Methylphenidate is currently a drug of abuse and readily prescribed to both
adolescents and adults. Chronic methylphenidate (MPH) exposure results in an increase
in DA in the motive circuit, including the caudate nucleus (CN), similar to other drugs of
abuse. This study focuses on research aimed to elucidate if there are intrinsic underlying
differences in the CN electrophysiological activity of animals exhibiting different chronic
responses to the same dose of MPH. Behavioral and caudate nucleus (CN) neuronal
activity following acute and chronic doses of MPH was assessed by simultaneously
recording the behavioral and neuronal activity. The experimental protocol lasted for 10
days using four groups; saline, 0.6, 2.5 and 10.0mg/kg MPH. Initially, the study
determined that animals exposed to the same dose of MPH exhibited either behavioral
sensitization or behavioral tolerance. Therefore animals were classified into two groups
(behaviorally sensitized/tolerant) and their neuronal activity was evaluated. Four hundred
and fifty one units were evaluated. Overall, a mixture of increases and decreases in CN
neuronal populations was observed at initial MPH exposure, and at ED10 baseline and
ED10 rechallenge. When separated based on their behavioral response
(sensitized/tolerant), significant differences in neuronal response patterns was revealed.
Animals exhibiting sensitization were more likely to increase their neuronal activity at
ED1 and ED10 baseline, expressing the opposite response at ED10 rechallenge.
Furthermore, when neuronal populations recorded from those animals exhibiting
behavioral sensitization were statistically compared to those from animals exhibiting
behavioral tolerance significant differences were observed. Collectively, these findings
tell us that animals exposed to the same dose of MPH can respond oppositely and
moreover that there is in fact some intrinsic difference in the two population’s neuronal
activity. This study offers new insight into the electrophysiological differences between
sensitized and tolerant animals.
v
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1 Introduction
The History of MPH and its Uses
Methylphenidate [Ritalin/MPH] was first synthesized in 1944 (U.S. Pharmacist,
2002), and by 1954, it was being tested on humans (U.S. Pharmacist, 2002). Initially in
1957, Ciba Pharmaceutical Company began marketing MPH as Ritalin for the treatment
of chronic fatigue, depression, psychosis, and narcolepsy (U.S. Pharmacist, 2002). In
1960, MPH was marketed as Ritonic, which was used as a treatment to improve a
patient’s mood and to maintain cognitive vitality (U.S. Pharmacist, 2002). By the 1970’s80’s, MPH was prescribed for the treatment of attention deficit hyperactivity disorder
(ADHD). The symptoms of ADHD, as described in the Diagnostic and Statistic Manual
for Mental Disorders (DSM IV), are as follows: inattention, hyperactivity, and impulsivity
for a period of at least six months that causes impairment both at home and at school or
work (DSM IV 1994 4th Ed.). From 1990-1999, a 500% increase in the use of MPH in
the United States was observed (U.S. Pharmacist, 2002) and the daily doses
administered to patients increased from 75 million in 1990 to 360 million in 1998
(Woodworth, 2000). Shockingly, the United States alone consumes 85% of the world’s
supply of MPH (Woodworth, 2000). Based on the 2000 US census population of
281,421,906, approximately one out of five hundred randomly chosen people are
currently prescribed Ritalin (Woodworth, 2000). MPH is still the pharmacotherapy of
choice and top seller for the treatment of ADHD.
Due to the overabundance of adolescents being prescribed MPH, there is a high
risk of nonmedical misuse and abuse by patients’ peers and family members. According
to the National Survey on Drug Use and Health, nonmedical use of a medication is
defined as;

“The use of prescription type psychotherapeutic drugs not prescribed for the
respondent by a physician or the use of a drug only for the experience or the
feeling it caused”
(www.oas.samhsa.gov).
Drug abuse is defined as
“The use of a drug for a nontherapeutic effect, and habitual use of drugs to alter
one’s mood, emotion, or state of consciousness”
(www.oas.samhsa.gov).
A substantial number of studies are available to support the assertion that MPH
is abused at a high rate by adolescents and adults (McCabe et al., 2007; Teter et al.,
2006; Wilens et al., 2006). One such study focusing on undergraduate college students,
found that over 30% of students that were tested had taken non-prescribed MPH either
to get high or to aid in studying (Teter et al., 2006; Wilens et al., 2006). In a 2006 study
of college students, McCabe et al. found that 16%of respondents abused stimulants for
the cognitive enhancement effect, with 96% of them preferring Ritalin/MPH as their drug
of choice (McCabe et al., 2007). Furthermore, a study involving 700 participants aged 12
to 44 found that 22.9% had loaned their prescription to someone else, 26.9% had
borrowed someone else’s medical prescription, and 39.4% were willing to share their
medication with family members (Goldsworthy et al., 2008). This study also reported that
20.8% of subjects between the ages of 18 and 25 borrowed prescription medication to
relax or feel good compared to only 10% of those aged 36 to 44 , indicating that younger
people are more likely to misuse and abuse MPH. In addition, this study reported that
34.1% of adolescents said they were more likely to use Ritalin/MPH if it came from
someone who was familiar with the drug (Goldsworthy et al., 2008). These statistics on
non-medical MPH use highlight the importance of performing further studies to examine
the short- and long-term effects of MPH exposure.
The behavioral effects following short-term MPH exposure have been well
documented (Brands et al., 1998), however, the data for long-term MPH exposure has
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not been fully investigated. The short-term behavioral effects associated with low doses
of MPH include wakefulness, appetite suppression, impairment of voluntary movement,
headache, heightened alertness,, and vomiting (Brands et al., 1998). The short-term
behavioral effects for higher doses of MPH include exhilaration, dilation of pupils,
agitation, muscle twitching, excitation, confusion, hallucinations, increased blood
pressure, increased pulse rate, delirium, paranoia, seizures followed by coma, excessive
repetition of movements and meaningless tasks (Borcherding et al., 1990; Masand and
Tesar, 1996). Although there are few studies on the long-term effects of low and high
dose MPH exposure, one study employing positron emission tomography (PET) scans
found that extended use of MPH constricted blood flow to the brain (Wang et al., 1994),
which may causes an increase in blood pressure. Other behavioral studies on long-term
effects of MPH use yielded conflicting results (Wilens et al., 2003; Piazza et al., 1989;
Lambert , 1999; Robinson and Berridge, 1993). For instance, one study reported that
MPH treatment protected adolescents from later drug dependence (Wilens et al., 2003),
another reported MPH use created vulnerability to later drug exposure (Piazza et al.,
1989; Lambert, 1999; Robinson and Berridge, 1993), while yet another longitudinal study
reported that there was no direct correlation between adolescent or youth stimulant use
and later drug use (Barkley et al., 2003). Given the amount of conflicting results
observed in the literature, we believe that recording both behavior and neuronal activity
together will give us a better idea as to why these reports are conflicting.
A better understanding of the short- and long-term neural adaptations that
occur following MPH exposure is crucial, especially since a large population of those
consuming this drug are children with central nervous systems (CNS) that are not fully
developed. What is known about the mechanism of MPH action and neural responses
to acute and repetitive exposure is as follows: MPH has a chemical structure and
neuropharmalogical characteristics similar to drugs with a high probability of abuse, such
3

as cocaine and amphetamines (Teo et al., 2003; Volkow, 2001). MPH has a similar
mechanism of action as cocaine in that it acts as an indirect agonist by binding with high
affinity to the dopamine transporter, blocking dopamine (DA) re-uptake to the
presynaptic terminal, and thus increasing levels of extracellular DA in the synaptic cleft.
MPH is absorbed and metabolized via de-esterification to ritalinic acid (Faraj et al., 1974;
Wang et al., 1997; Wargin et al.,1983) and released into the urine within 48 hours. Since
the psychostimulant is concentrated in catecholaminergic systems with free flow across
the blood brain barrier, concentrations of MPH in the brain exceed plasma levels. MPH
also has a similar rapid uptake in the brain as cocaine, however MPH has a much lower
rate of clearance (Morse et al., 1995). This may explain why IV or intranasal
administration of MPH yields higher mortality rates than cocaine or amphetamines
(Gatley et al., 1999; Volkow et al., 1995, 1996, 1999).
It has also been shown that dose and route of MPH administration play a
significant role in the experience of the user, as behavioral responses and
neurochemical reactions to the drug are dependent upon the length of time it takes for
the drug to reach its peak level in the periphery (Kuczenski and Segal., 2002). When
MPH is administered orally, it is absorbed through the intestinal tract, has a half-life of
about 1 hour, and peaks in the blood stream at approximately 60-90 minutes (Gerasmiov
et al., 2000; Kuczenski and Segal 2002; Stewart & Badiani 1993) (Garland 1998;
kuczenski and Segal 1991;2001; Solanto 1998, 2000). However, following intravenous
(IV) injection or intraperitoneal (IP) administration, peak levels of MPH in the periphery
are reached at approximately 8-20 minutes and 15-28 minutes, respectively (Gerasmiov
et al., 2000; Kuczenski and Segal 2002; Stewart & Badiani 1993). The ability to reach
peak levels rapidly (8-30 minutes) is one of the main factors responsible for both the
euphoric/pleasure response and adverse effects, such as a sensitization response.
Behavioral Sensitization and Tolerance with MPH Use
4

MPH has been shown to cause different behavioral responses even when
subjects are given the same dose of the drug. Some studies report that MPH elicits
behavioral sensitization, whereas other studies report the same dose of the drug can
also result in behavioral tolerance (Barron et al., 2004; Eckerman et al., 1991; Gaytan et
al., 1996, 2000; Yang et al., 2003; 2006, 2007). The aim of the latter study was to first
determine if there are differences in neuronal responses in individuals, particularly with
respect to neuronal firing patterns in the caudate nucleus (CN), and whether these
differences are responsible for the conflicting reports on behavioral responses with
chronic MPH exposure. We hypothesized that animals will exhibit different overall
neuronal responses depending on whether that animal exhibits behavioral sensitization
or behavioral tolerance. Furthermore, we specifically hypothesize that an increase or a
decrease in neuronal responses directly correlates to behavioral sensitization or
tolerance, respectively.
Several reviews suggest that behavioral tolerance and sensitization are phenomenon
in animals that represent an enduring response to medications even after the
discontinuation of drug use (Laasko et al., 2002), and are used as a model for drug
craving and dependence (Kalivas et al., 1998; Robinson and Berridge, 1993; Wolf,
1998). Behavioral sensitization is defined as the increased amplification of activity
resulting from repetitive administration of psychostimulants (Chao and Nestler, 2004;
Gaytan et al., 1997; Kalivas and Stewart, 1991), and occurs in two phases: induction
and expression. In the induction phase, transient changes occur following repetitive
psychostimulant administration that subsequently result in increased behavioral activity.
The expression phase is characterized by persistent long-lasting neural changes that
result in sustained augmented behavioral responses despite cessation of
psychostimulant use (Pierce and Kalivas, 1997). Thus, equal or increased behavioral
activity is observed when animals are given a re-challenge administration of drugs
5

following a period of time when the drug is no longer in their system. It is generally
believed that behavioral sensitization occurs due to synaptic plasticity in the reward
circuit, including the CNS structures: the nucleus accumbens (NAc), prefrontal cortex
(PFC), caudate nucleus (CN), etc.
The Role of the Claudate Nucleus in Responses to MPH
The CN is part of the basal ganglia and receives input from different cortical areas,
including the thalamus and substantia nigra, which ascend to the globus pallidus
(Carpenter 1976; Kande et al., 2000). The main efferent projections come from the
globus pallidus and project to the thalamus via the ansa lenticularis and lenticular
fasciculus. From the thalamus projections extend to the cortex via the paliotegmental
neurons which continue to cover several subcortical areas (Carpenter, 1976). The CN
contains both a direct excitatory pathway and an indirect inhibitory pathway, which are
modulated by the activation of CN medium spiny neurons (MSN) that express D1 and
D2 dopamine neurons. The CN is stimulated by the cortex to release the
neurotransmitter gamma amino-butyric acid (GABA), which will project to the globus
pallidus external (GPe) via the indirect pathway. However, using the direct pathway,
GABA will project to the globus pallidus internal (GPi). GPe inhibition leads to
suppression of the subthalamic nucleus, resulting in disinhibition of the GPi and
ultimately, inhibition of motion through GPi's suppressive action on the thalamus. GPi
inhibition (through the direct pathway) causes disinhibition of the thalamus, thereby
allowing motion (Carpenter, 1976; Kreitzer and Malenka, 2008; Zhang et al., 2004)(Fig.
1). This gives rise to the hypothesis that the dominant role of the CN is to regulate motor
performance (Zhang et al., 2004).
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Figure 1 shows the direct (excitatory) and indirect (inhibitory) pathway of the CN. The
direct pathway receives projections from the globus pallidus internal and substantia nigra
reticular via the thalamus and other cortical areas. The indirect pathway receives
projections from the globus pallidus external via the subthalamic nucleus and thalamus.
*Rights for reuse of figure obtained through Sinauer associates.
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The CN has been reported to be structurally altered by acute and repeated
administration of MPH. These alterations include the regulation of the transcription
factors CREB and ∆Fos B, both implemented in drug dependence (Chao and Nestler,
2004; Nestler 2004, 2008). The CN direct pathway contains an over abundance of D1
DA receptors which control extracellular signal-kinase (ERK). ∆Fos B gene expression
is increased by the upregulation of ERK which has been reported to induce long-term
neuroadaptions in the brain (Shi and McGinty, 2010 and Zhang et al., 2004). ∆Fos B
elevation is correlated with increased reliance to the behavioral effects and increased
motivation for the drug (Nestler, 2001; 2004; 2008). D1 receptor inhibition by blockade or
ablation results in an increase in phosphorylation of cAMP response element binding
protein (CREB), inhibiting the excitatory responses (Ferguson et al., 2010). Thus we
hypothesized that animals expressing behavioral sensitization will also show an increase
in extracellular neuronal responses following chronic drug exposure.
MSNs of the indirect pathway coexpress an abundance of D2-like DA receptors
which exert inhibitory effects (Kreitzer and Malenka, 2008; Zhang et al., 2004). Using
D3-like DA receptor (subset of D2 receptors) mutant mice Zhang et al. (2004) exhibited
an increase in ERK activation, thus increasing sensitivity to the drug.. Previous studies in
the NAc report that CREB activation via psychostimulants creates a homeostatic
negative feedback adaption, inhibiting sensitivity to future drug administration (Chao and
Nestler, 2004 and Nestler, 2004). Therefore I hypothesized for those animals expressing
behavioral tolerance will exhibit decreased neuronal firing patterns after chronic MPH
exposure.
Previous studies reported that the ablation of the CN by nonspecific electrolytic
lesion and specific ablation of the DA system by 6-OHDA that destroyed the nerve
endings of the DA system (Claussen et al., 2012) found that the electrolytic lesion
8

animals maintained their response to chronic MPH exposure, however, the 6-OHDA
lesion group did not respond to the acute and chronic MPH administration. Owing to the
response following 6-OHDA lesion and no response to the electrolytic lesion we know
that the push pull mechanism described earlier involves DA transmission (Claussen et
al., 2012). Therefore, an upset of the balance between the direct and indirect pathways
is mediated by the DA system and moreover the DA system will mediate the responses
observed during the current study.
Previous neurophysiological studies targeting the reward circuit independent of the
animals behavioral activity show that 2.5 mg/kg MPH modulates the neuronal activity of
the CNS sites; NAc, PFC, CN following both acute and chronic MPH exposure (Chong et
al., 2012; Claussen and Dafny, 2012; Salek et al., 2012)
In this study, we endeavored to compare neuronal responses and behavioral
responses to acute and chronic MPH use and determine whether there are any
relationships that can be made between these responses. We hypothesized that
animals exposed to the same dose of MPH will exhibit different behavioral responses;
some exhibiting behavioral sensitization and others behavioral tolerance. Also, we
hypothesized that when these animals are separated based on their behavioral
responses of sensitized or tolerance, their neuronal responses will be statistically
significantly different. We chose to investigate this hypothesis using a rodent model, as
the relationship between drug doses (milligrams of hydrochloride salt/kilogram of body
weight) and percentage occupancy of the dopamine transporter (DAT) is identical for
cocaine and MPH in both rodents and humans (Gately et al., 1999). We believe that

finding a correlation between the neuronal and behavioral properties of animals in
response to acute and chronic MPH will give us insight into why conflicting results are
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observed across both animal and human studies that investigate the long term adaptations
occurring in response to chronic MPH exposure.
Methods
2. Experimental Procedure
2.1 Subjects
Forty-seven (47) adult male Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) were
obtained.
The animals weighed 150-175 grams upon arrival and were housed in single
Plexiglas cages inside a sound-attenuated animal facility room for acclimation.
The rats homecage used during the acclimation was also used as their test cage
throughout experiment. The room was maintained on a 12-h light/dark cycle
(lights on 06:00), at an ambient temperature of 21 ± 200C and at a humidity of 5862%. Rats were supplied food and water ad libitum for the entire duration of the
study. All experiments were approved by our Animal Welfare Committee and
carried out in accordance with the National Institute of Health Guide for Care and
Use of Laboratory Animals.
Chong et al., 2012
2.2 Drug
Methylphenidate hydrochloride (MPH) was obtained from Mallinckrodt Inc. (St. Louis,
MO, USA). A study from 289 patients treated with MPH reported that the range of doses
ingested by these patients was from 0.06 to 29.3 mg/kg with the majority of patients
being treated with 1.0 to 3.0 mg/kg MPH. Approximately 2 to 3 mg/kg (i.p.) MPH (White
and Yadao 2000) in rodents achieved plasma levels similar to those achieved in clinical
use (Bowman and Kuhn, 1996; Brandon and Steiner, 2003; Gerasimov et al., 2000).
MPH doses between 0.5 to 3.5 mg/kg, i.p., were reported to promote peak plasma
concentration within the typical clinical range (Kuczenski and Segal, 2002). In rodents, a
MPH dose below 5.0 mg/kg, i.p., is considered a low dose and is comparable to doses in
clinical use. The range of 5 to 10 mg/kg MPH is considered moderate dosage and
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above 10 mg/kg as a high dosage (Bowman and Kuhn, 1996; Brandon and Steiner,
2003; Faraj et al., 1974; Kollins et al., 2001; Rush et al., 2001; Sagvolden and Sergeant,
1998; Santosh and Taylor, 2000; Solanto, 1998, 2000; Spear et al., 1983; Stewart and
Badiani, 1993). Previous work using MPH doses from 0.1 to 40 mg/kg i.p. showed that
doses of 0.6, 2.5 and 10.0 mg/kg MPH administered intraperitoneal (i.p.) elicited
behavioral sensitization or tolerance (Askenasy et aI., 2007; Dafny and Yang, 2006;
Gaytan et aI., 1997b; 2000; Yang et aI., 2006a; 2007), therefore these were the three
doses chosen (0.6, 2.5 and 10.0mg/kg). The MPH was dissolved in 0.9% saline (NaCI)
solution and the dose was calculated as free base. All injections were given between
08:00am and 9:00am and equalized to 0.8 ml with saline so that all injections volumes
were the same for all animals.
2.3 Electrode Implantation
On the day of surgery rats were weighed and anesthetized with 50 mg/kg i.p.
pentobarbital. The top of the rat's head was shaved to expose the skin and
coated with a thin layer of 2% Lidocaine Hydrochloride Jelly (Akorn,lnc.). The
animal was then placed in a stereotaxic instrument. An inch incision was made
with muscle and connective tissue removed to expose the skull. A single hole for
the reference electrode was drilled above the frontal sinus and two bilateral
0.6mm diameter holes were drilled over the CN, all in accordance to the
coordinates derived from Paxinos and Watson (1986) rat brain atlas (1.0mm
anterior from bregma, 3.0mm lateral). Prior to electrode placement 6 anchor
screws were put in vacant areas of the skull to secure the skull cap with dental
acrylic cement. Two twisted Nickel-Chromium, Diamel coated; 60 micron
diameter wire electrodes (fully insulated except at tips) were secured each to a
1cm copper connector pin made prior to surgery. A reference electrode was
placed in the frontal sinus and the two twisted recording electrodes were
implanted each in the CN as follows: One twisted electrode (i.e., two electrodes
together) was inserted into the drilled hole at an initial depth of 4mm. Unit activity
was monitored during placement of electrodes by using a Grass emitter Hi Z
Probe connected to a Grass P511 series pre-amplifier. Electrodes were fixed to
the skull only when spike activity exhibited at least a 3:1 signal to noise ratio in
both electrodes. If the activity did not match the 3:1 spike to noise ratio criteria,
the electrode was moved down in approximate increments of 10 microns until a
depth of 5.0mm until they displayed a proper signal to noise ratio of neuronal
activity. Once a sufficient signal was obtained, the electrode was fixed in the skull
with Webglue, cyanoacrylate surgical adhesive (Webster Veterinary). The
secondary twisted electrode was implanted using identical procedures in the
other hemisphere (Chong et al., 2012; Claussen and Dafny, 2012; Dafny, 1982;
11

Dafny et al., 1983; Dafny and Terkel, 1990; Yang et al., 2006a; 2006b; 2006d;
2007). The electrode connector pins were inserted into Amphenol plugs which
were positioned on the skull and secured to the skull with dental acrylic cement.
Rats were allowed to recover from the surgical procedure for approximately 4 to
7 days. During this recovery period, every day for 2 hours, the rat, with his home
cage, was placed in the experimental behavioral apparatus and connected to the
wireless (telemetric) head stage transmitter (Triangle BioSystems, Inc; Durham,
NC, USA) for daily acclimation to the recording systems.
Chong et al., 2012
On the first day of recording the animals weighed between 200 and 220grams,
postnatal days P62-65.
2.4 Experimental protocol
Animals were randomly assigned to four groups; saline, 0.6, 2.5 or 10.0 mg/kg MPH
groups. The experimental protocol was adapted from previous experiments (Chong et
al., 2012; Claussen and Dafny 2012, Salek 2012). Experimentation began 4 to 7 days
post-surgery and lasted for 10 days. On experimental day 1 (ED1) prior to the start of the
recording session, animals were again allowed to acclimate to the recording system for
20-30 minutes. During this time, the recording parameters were organized in order to
properly record the neuronal activity and save the files. Immediately post saline (0.8 ml
of 0.9%) injection, a 60 min baseline of neuronal and behavioral activity was recorded
simultaneously. This was followed by a second injection of saline or 0.6, 2.5 or 10.0
mg/kg MPH injection and recordings were resumed immediately after injection for
another 60 minutes. From ED2 to ED6 rats were injected once daily with the same MPH
concentration and at the same time as they have been injected at ED1. All injections
were done in their home cages (which were also their test cages), ED7 to ED9 were
washout days in which no injections were given. On ED10, identical experimental
protocol as ED1 was followed (Table 1); neuronal and behavioral baseline activity was
recorded for 60 min following a saline injection, as well as an additional 60 min neuronal
and behavioral recording after a saline or MPH rechallenge injection (table 1).
12

Table 1: Experimental Protocol

Experimental
Days:

Day 1

Day 2 to 6

Day 7 to 9

Day 10

Acute (initial)

Maintenance

Washout

Rechallenge

Saline
N=10

saline / saline

saline

Washout

saline / saline

saline / 0.6 mg/kg

0.6 mg/kg

Washout

saline / 0.6 mg/kg

saline / 2.5 mg/kg

2.5 mg/kg

Washout

saline / 2.5 mg/kg

saline / 10.0 mg/kg

10.0 mg/kg

Washout

saline / 10.0 g/kg

Treatment:

0.6 mg/kg
N=12
2.5 mg.kg
N=12
10.0 mg/kg
N=12
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2.5 Behavioral Recording System
Locomotor activity was recorded using an open field computerized animal activity
system (Opto-M3, Columbus Instruments, Columbus, OH). The open field system
comprised of a clear acrylic cage with infrared beam sensors that run 40 cm in length, by
20 cm in width with 16 by 8 infrared beams respectively, and their sensors set 5 cm
above the floor of the cage. Movement across any of the infrared beams results in a
beam break and was subsequently recorded as total counts (TC) of locomotion. TC's
were compiled and downloaded to a PC in 10 minute bin increments and were evaluated
from 60 min post injection for both the saline baseline and MPH administration on ED1
and ED10. The Opto-M3 software was used to count the number of stereotypic
movements (NOS) was calculated manually by subtracting the horizontal activity from
the total counts of locomotion. The objective of the behavioral recoding was to
distinguish animals that expressed behavioral sensitization following repeated MPH
exposure from animals that expressed behavioral tolerance. This grouping would be
used as the basis for the neurophysiological data analyzing.
2.6 Behavioral Analysis
The locomotor activity recorded on ED1 and ED10 was summed into 10 min bins for 60
min (i.e.6 bins/hr). The TC and NOS were then analyzed for each individual rat using a
paired t test with significance set at P<0.05. Three comparisons were made: (1) ED1
baseline compared to ED1 post MPH administration to determine the acute effect of the
drug (Table 1); (2) ED10 baseline compared to ED1 baseline to evaluate whether the six
daily MPH exposures and the three washout days elicits changes on ED 10 baseline
compared to ED1 baseline activity (3) ED10 MPH chronic effect compared to ED1 MPH
acute effect to determine if behavioral sensitization or tolerance was expressed (Table1).
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Based on the third comparison, the animals were divided into two groups of either
behaviorally sensitized or no change/tolerant. As a group the rats were then analyzed
(for all three comparisons) using an ANOVA with repeated measures with adjustments
for correlation among measurements. Post ad hoc comparisons were used to estimate
changes between days within groups.
2.7 Electrophysiology Data Acquisition
On the experimental recording day, the rat was placed with his home cage in a
Faraday testing box to reduce noise during signal transmission. The wireless
Triangle Bio Systems (Durham, NC, USA) head stage was connected to the
electrode pins of the skull cap. The Triangle BioSystem head stage sent neuronal
activity signals through a receiver that connects to a Cambridge Electronic
Design (CED) analog –to- digital converter (Micro1401-3; Cambridge, England)
which then collected and stored the recorded data on a PC. Spike 2.7 software
(CED) was used off line to sort for identical spike amplitude and waveforms by
examining single spike activity exhibiting similar amplitude and wave form
patterns before and after MPH administration for ED1 and ED10 (See section
2.7.2 on spike sorting for more details) to produce a sequential frequency
histogram and to calculate the firing rate in spikes per second. Approximately
one to two spikes (units) were analyzed per electrode.
Chong et al., 2012
2.8 Spike sorting
For spike sorting Spike2 version 7 software (Cambridge Electronics DesignCED) was used. The analog recording (sampling rates up to 200 kHz) was
captured by the program and processed using low and high pass filters (0.3-3
kHz). Two window levels were set, one for positive-going spikes and one for
negative-going spikes. Spikes with peak amplitudes that were triggered by the
window were used to create templates. One 1000 waveform data points was
used to define a spike. The spikes were extracted when the input signal enters
an amplitude window. Spikes with a peak amplitude outside these limits were
rejected. The algorithm that was used to capture a spike allowed the extraction of
templates that provide high-dimensional reference points that can be used to
perform accurate spike sorting, despite the influence of noise, spurious threshold
crossing and waveform overlap. All temporally displaced templates were
compared with the selected spike event to find the best fitting template that yields
the minimum residue variance. Secondly, a template matching procedure is then
performed; when the distance between the template and waveform exceeds
some threshold (80%) the waveforms were rejected. That means that the spike
sorting accuracy in the reconstructed data is about 95%. All these parameters of
spike sorting for each electrode were sorted and used for the activity recorded in
experimental day 1 (ED1) and in ED10 i.e., we use identical criteria to sort spikes
15

in ED1 and ED10 to ensure the spike pattern captured on ED1 is the same as
ED10.
Claussen et al., 2012
2.9 Electrophysiological Data Analysis
The sorted neuronal activity obtained from the fixed template matching system
was converted by the spike 2 version 7 software (CED) into their firing rates
(spikes per second) for the baseline control recording and for the activity
following MPH administration. These firing rates were exported into a spread
sheet format displaying the rat's number, experimental day, MPH dose and
recording channel (to distinguish hemisphere). Firing rates were evaluated for
normality assumptions to determine parametric or non-parametric methods to
evaluate differences before and after MPH treatments. The firing rates were
determined to not hold normality assumptions, so we assessed differences in
mean firing rates by using the critical ratio (CR) test.
Chong et al., 2012
This test was used to determine whether acute and chronic MPH treatments altered CN
unit activity (C.R.=E-C/√   ± l.96=P<0.05) when comparing the effect of the initial
(acute) MPH exposure, C – represents the activity following saline and E – the activity
post MPH injection; when comparing the effect of six daily MPH exposures and three
washout days on ED10 baseline C – represents the ED1 baseline, and E – represents
the ED10 baseline activity; when comparing the effects of MPH rechallenge at ED10 to
ED1; E represents the effects of MPH at ED10, and C represents the ED1 neuronal
activity post MPH injection. In addition changes of each unit activity induced by the
treatment was considered statistically significant if the firing rate after drug treatment
differed by at least 2 standard error (S.E.) from the mean. (Claussen and Dafny, 2012;
Dafny, 1980; 1982; Salek et al., 2012).
Multiple approaches were used to further analyze the neuronal activity based on
the behavioral responses. First a natural log odds ratio was utilized to determine the
likelihood of one group of animals to show an increase in neuronal activity compared to
the other group of animals (comparing the neuronal population recorded from
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behaviorally sensitized group to those recorded from animals exhibiting tolerance). This
was done for all three comparisons; the initial (acute) MPH injection, the baseline
neuronal activity at ED10 compared to baseline at ED1 and the rechallenge MPH
administration at ED10 compared to ED1 initial MPH injection. To compensate for the
smaller values observed on certain days for varying doses, 0.5 was added to all
numbers for computation of the odds ratio. A number of 1 and higher in the odds ratio
test indicates a higher likelihood of increased neuronal activity in one group compared to
the other group of animals, conversely a number smaller than 1 represents a less likely
increase in neuronal activity.
A log linear model was used next to control for dose when comparing the overall
activity (acute, baseline and chronic) between the two groups (behaviorally tolerant and
sensitized) to determine if there was a significant difference between dose behavior and
firing patterns for each group (0.6, 2.5 and 10.0 mg/kg). P-values of <0.05 obtained
from the log linear model was considered as significant.
2.10 Histological verification of electrode placement
At the end of the experimental protocol, rats were deeply anesthetized with
sodium pentobarbital. The rat's brain was transcardially perfused with 10%
formalin solution containing 3% potassium ferrocyanide. A 2 mA DC current was
passed through the electrode connector pin for 40 seconds to produce a small
lesion. The brain was then excised and stored in 10% formalin for subsequent
histological processing. Placements of the electrodes were verified in 60 micron
thick coronal sections that were stained with cresylviolet. Coordinate position of
the electrode tips were established by matching equivalent locations of the lesion
and the prussian blue spot by using the Rat Brain Atlas by Paxinos and Watson
(1986) (Fig. 2).
Chong et al., 2012
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+0.70
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+0.48
-0.40

Caudate
Nucleus

Figure 2 reconstructs the histologically verified electrode tip placement in the caudate
nucleus (CN). The black dots on the rat atlas plates (Paxinos and Watson, 1986)
represent the location of the CN recording electrodes in serial coronal sections. The
number on the top right corner of each section represents the anterior/posterior distance
(mm) from bregma. *Rights for reuse of figure obtained through Elsevier.

→
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3 Results
3.1 Overall
3.1.1 Overall Behavioral
Forty-seven (47) rats that met the histological verification of electrode location placement
and the neurophysiological requirements and exhibited similar spike amplitude and
pattern at ED1 and ED10 were included in the study (saline N=10; 0.6 mg/kg N = 12; 2.5
mg/kg N = 13; 10.0 mg/kg N = 12 animals respectively). Each animal’s Total counts (TC)
of activity were evaluated separately using a paired t-test to determine whether they
exhibited behavioral sensitization or tolerance. This was done by comparing their
locomotor activity after MPH administration at ED10 to the effect of the initial MPH
exposure on ED1 (Table 1). The number of stereotypic movements (NOS) was analyzed
as a second measure to verify that animals exhibiting tolerance or no change were not in
fact exhibiting an increased stereotyped behavior; a form of behavioral sensitization. The
NOS results show that all animals expressing behavioral tolerance also exhibited
statistically (p<0.05) significant decreases in stereotypic movement (data not shown).
The control group showed no effect on behavioral activity following acute or multiple
injections of saline (data not shown). This lack of change in behavioral activity following
saline injection shows that our recording procedures have no effect on the rats
locomotor activity.
3.2 Overall Saline
Sixty CN units were recorded from 10 rats injected with saline only. In general these CN
units exhibited similar neuronal firing activity at ED1 following the second saline injection
compared to the initial saline injection. Their baseline activity at ED10 following six daily
saline injections compared to the activity at ED1 showed that the units exhibited similar
neuronal activity at ED1 and at ED10. This observation in the saline control group
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provides evidence that daily handling and injection volume did not modulate the CN units
neuronal firing rates.
3.3 Results (0.6mg/kg)
3.3.1 Behavioral Results (0.6mg/kg)
As a group, the 0.6mg/kg MPH dose had no effect on acute and chronic
behavioral response (Fig. 3A). This lack of response as a group is due to some
individual animals increasing locomotion and others decreasing their locomotion, thus as
a group they cancel each other out. However, when each animal was analyzed
individually and grouped based on their response (sensitized or tolerant) to chronic
MPH; four animals treated with 0.6 mg/kg MPH exhibited significant [F1,6=5.98,P=.03]
behavioral sensitization (Fig. 3B), the eight animals that individually exhibited no change
(tolerance) in activity also showed no significant [F1,14=4.6, P=0.2] (Fig. 3C) changes in
activity as a group. Thus, the 0.6mg/kg MPH gave two responses; significantly
sensitized and non significant tolerance. These differences were further evaluated by
their neuronal responses to elucidate an intrinsic difference as previously hypothesized.
3.3.2 CN Neuronal (0.6 mg/kg, Table 2A)
A total of 101 units were recorded from the CN following acute and chronic 0.6 mg/kg
MPH administration. 80 of the units responded to acute 0.6 mg/kg MPH administration,
the majority 48/80 of the CN MPH responsive units showed an increase in their neuronal
activity while 32 CN units exhibited attenuation of their neuronal activity (Table 2A, under
acute). When ED10 baseline neuronal activity was compared to ED1 baseline neuronal
activity, all CN units exhibited significant (p<0.05) changes, with the majority 70/101
exhibiting a decrease in baseline neuronal activity (Table 2A, under baseline). MPH
rechallenge at ED10 elicited in all CN units significant (p<0.05) changes in their neuronal
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firing rates compared to ED1 initial MPH, with the majority of the CN units, 65/101,
exhibiting an attenuation of activity (Fig. 4B) and 36/101 exhibited increased neuronal
firing rates (Table 2A, under rechallenge; Fig. 4A). The balance of increased/decreased
neuronal firing patterns underlies the respective lack of behavioral response to 0.6mg/kg
MPH.
3.3.3 CN neuronal based on behavior (0.6mg/kg, Table 2B and 2C)
Table 2B and 2C summarizes the CN unit responses to 0.6mg/kg MPH based on their
behavioral responses to chronic MPH (comparing the effect of MPH at ED10 to ED1).
The natural log odds ratio shows that for the acute MPH exposure to 0.6 mg/kg, the
animals expressing behavioral tolerance (Table 2C) were more likely, (ln .046) to show
an increase in neuronal activity. This increase in neuronal responses for the behaviorally
tolerant animals explains why those same animals showed a higher increase in
behavioral activity at ED1 compared to those exhibiting sensitization. For the baseline
neuronal activities at ED10 compared to ED1 and at ED10 rechallenge MPH
administration the odd ratio showed that the behaviorally sensitized (Table 2B) were
likely to show increased neuronal activity with a score of ln1.0, ln 0.322. Therefore as
previously postulated the animals exhibiting behavioral sensitization did in fact show an
increase in their neuronal firing patterns. However when neuronal responses were
statistically compared for those exhibiting behavioral sensitization to those neuronal
responses for those exhibiting behavioral tolerance, no significant differences [df 2;
x2:3.08, p=0.2] were observed. The CN is a motor structure, 0.6mg/kg MPH is
considered a low dose therefore the lack of statistical difference between the two groups
could potentially be due to 0.6 mg/kg having minimal effect on the CN.
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Figure 3: 3A the top histogram summarizes the overall behavioral (N=12) response to
acute and chronic 0.6mg/kg MPH. The bottom histogram separates the animals based
on their individual response of either behaviorally sensitized, (N=4) (3B) or behaviorally
tolerant (N=8) (3C). * represents significant (p<0.05) differences. ED = experimental day;
v= compared to; BL =baseline activity; MPH = methylphenidate.
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Table 2

All animals

Animals Exhibiting
Behavioral
Sensitization

Animals Exhibiting
Behavioral
tolerance

B) 0.6mg/kg (N=32)

C) 0.6mg/kg (N=69)

.

A) 0.6 mg/kg total
(N=101)
Acute
ED1

Baseline
(ED10 to
ED1)

Rechallenge
(ED10)

Acute ED1

Baseline
(ED10 to
ED1)

Rechallenge
(ED10)

Acute ED1

Baseline
(ED10 to
ED1)

Rechallenge
(ED10)

increase ↑

48

31

36

19

15

12

29

16

21

decrease ↓
No change
≠

32

70

65

13

17

20

19

53

48

21

0

0

0

0

0
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0

0
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Baseline ED1
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ED1 MPH

Baseline ED10
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Figure 4A: The figure shows a representative firing rate histogram of a CN units
exposure to 0.6mg/kg MPH. To the left shows the baseline activity at experimental day
(ED) 1 baseline, followed by initial MPH exposure. To the right the first histogram shows
the baseline firing activity of the CN unit at ED10, followed by MPD rechallenge
rechalleng activity
at ED10. In the upper corners are 20 super imposed spikes during the control, initial
MPH exposure at ED1 and control and rechallenge MPH exposure at ED10. The spikes
show that identical spike
CN
N units exposure to 0.6mg/kg MPH.
Figure 4B shows a representative histogram of a C
To the left shows the baseline activity at experimental day (ED) 1 baseline, followed by
ED1 drug initial exposure. To the right the histogram shows the baseline firing activity of
the CN unit at ED10 baseline, followed by decrease in firing at the rechallenge activity
on ED10.
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3.4 Results (2.5mg/kg)
3.4.1 Behavioral Results (2.5mg/kg)
The 2.5 mg/kg MPH group showed no significant change in activity when
comparing the effect of the drug at ED10 MPH rechallenge to MPH given at ED1 (Fig.
5A). This lack of response is due to some individual animals increasing their activity and
some individual animals decreasing their behavioral activity, so when grouped together
their activity averages to an amount close to baseline. Analyzed individually, seven
animals exhibited behavioral sensitization to 2.5mg/kg MPH, and significant [F1,7=4.74,
P=0.01] differences in behavioral activity at ED10 rechallenge compared to ED1 acute
injection (Fig. 5B). This significant increase in behavioral activity is expected when you
look at table 3B, under rechallenge, nearly all units responded majority of excitatory
responses are observed. Five animals exhibited behavioral tolerance when analyzed
individually however as a group they did not exhibit significant [F1,8=5.31,P=0.13]
differences in locomotor activity(Fig. 5C). Table 3C under baseline shows that the
majority of responses are inhibitory, therefore when the rechallenge was administered
less units responded with increased activity. This inhibition in neuronal firing rates lead
to a reduced behavioral response compared to the day one drug. Similar to the 0.6mg/kg
dose, 2.5mg/kg MPH gave two responses: significantly sensitized and not significantly
tolerant. Furthermore as above mentioned these responses show a correlation to the
respective neuronal responses, further detailed below.
3.4.2 CN Neuronal (2.5 mg/kg, Table 3A)
A total of 117 CN units were recorded following acute and chronic 2.5 mg/kg MPH
administration (Table 3). 66/117 of the CN units responded with significant increases in
neuronal activity (p<0.05) to acute 2.5 mg/kg MPH administration (Table 3A, under
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acute). This increase in neuronal responses elucidates why a significant increase in
behavioral activity was seen (Table 3A). ED10 baseline neuronal activity compared to
ED1 baseline showed that 116/117 CN units exhibited significant (p<0.05) change in
their baseline neuronal firing patterns, with the majority, 78/116, decreasing their
neuronal firing rate at ED10 compared to ED1 (Table 3A, under baseline; Fig. 6A). MPH
rechallenge at ED10 resulted in 106 of CN units responding with significant (p<0.05)
changes in their neuronal firing rate when compared to the effect of the acute 2.5 mg/kg
administration. Of the 106 CN units responding to MPH, 88 exhibited an increase in their
neuronal firing rates (Table 3A, under rechallenge; fig. 6B); whereas the other 18/106
decreased their neuronal firing rates.
3.4.3 CN neuronal based on behavior (2.5 mg/kg, Table 3B and 3C)
Table 3B and C summarizes the CN unit responding to 2.5mg/kg based on their
behavioral responses to chronic MPH. The natural log odds ratio shows that for the
acute exposure to 2.5mg/kg MPH the animals expressing behavioral tolerance were
more likely, (ln 2.7) to show an increase in neuronal activity. This increase in neuronal
activity for animals expressing behavioral tolerance is also seen in their acute behavioral
activity. They show a higher increase in activity following initial drug exposure versus the
sensitized animals. For the baseline neuronal activities at ED10 compared to ED1 the
behaviorally sensitized were likely to show increased neuronal activity with a score of ln
1.47, while at ED10 rechallenge MPH administration the odd ratio showed that the
behaviorally tolerant animals were more likely to show an increase in activity ln 0.362.
When a statistical comparison was made from the neuronal responses of those
exhibiting behavioral sensitization to the neuronal responses of those exhibiting
behavioral tolerance, as hypothesized, a significant difference was observed [df 2:
x2:30.41, p=0.001]. This difference between the two groups implies that there are
26

intrinsic differences within animals that can cause them to respond differently to the
same dose of MPH.
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Figure 5A top histogram summarizes the overall (N=12) behavioral response to acute
and chronic 2.5mg/kg MPH. The bottom histogram separates the animals based on their
individual response of either behaviorally sensitized (N=7)(left 5B) or behaviorally
tolerant (N=5)(right 5C). * represents significant (p<0.05) differences. ED = experimental
day; v= compared to; BL =baseline activity; MPH = methylphenidate.
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Table 3
Animals Exhibiting
Behavioral
Sensitization

All animals
A) 2.5 mg/kg total
B) N=117

Animals Exhibiting
Behavioral
tolerance

C) 2.5mg/kg
D) N=66

C) 2.5 mg/kg
N=51

Acute
ED1

Baseline
(ED10 to
ED1)

Rechallenge
(ED10)

Acute ED1

Baseline
(ED10 to
ED1)

Rechallenge
(ED10)

Acute ED1

Baseline
(ED10 to
ED1)

Rechallenge
(ED10)

increase ↑

66

38

88

23

30

46

43

8

42

decrease ↓

31

78

18

28

35

16

3

43

10

No change
≠

20

1

11

15

0

9

5

1

2

29
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Figure 6A: The figure is a representative histogram showing the baseline activity
expressed for the majority of CN units at ED1 (left side) with the
he baseline at ED10 (to the
right). This CN unit showed significantly decreased neuronal firing rates compared to the
initial baseline firing activity prior tto 2.5 mg/kg MPD administration.
Figure 6B: The figure shows a representative histogram of CN firing rates that did not
respond to initial MPH injection (to the left) however at ED10 rechallenge (histogram to
right) the MPH exposure elicited an increased in this CN u
unit’s neuronal firing response,
exhibiting neurophysiological sensitization.
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3.5 Results (10.0mg/kg)
3.5.1 Behavioral Results (10.0mg/kg)
10.0mg/kg MPH administration resulted in significant increased behavioral
activity at ED1 initial exposure and following MPH rechallenge at ED10 (Fig. 7A).
Analyzed individually, two animals exhibited behavioral sensitization, and when
statistical evaluated, they did not exhibit significant [F1,2=18.53, P=0.9] (Fig. 7B)
differences, due to the small N value. Ten animals exhibited behavioral tolerance, and
exhibited significant [F1,18=4.41, P=0.01] attenuation post MPH rechallenge at ED10
when compared to MPH exposure at ED1 (Fig. 7C).
This data shows that the same dose of chronic 10.0mg/kg MPH in some animal’s
elicited behavioral sensitization and in others behavioral tolerance.
3.5.2 CN neuronal Results (10.0mg/kg, Table 4)
A total of 135 units were recorded from the CN following acute and chronic 10.0 mg/kg
MPH (Table 4A). The majority of the CN units, 121/135 responded with significant
(p<0.05) changes in neuronal activity following acute 10.0 mg/kg MPH administration
(Table 4A, under acute). Of the 121 CN units responding to acute MPH, 90 exhibited
significant (p<0.05) increase in their neuronal firing rate activity compared to their saline
baseline activity. This overall increased neuronal firing pattern in the CN elucidates why
the animals as a group showed significant increased locomotor activity. At ED10, all of
the CN units exhibited significant (p<0.05) changes in their ED10 baseline neuronal
firing compared to ED1 baseline (Table 4A, under baseline), with the majority of them,
101/135, exhibited decreases in their neuronal firing rates. All CN units responded with
significant (p<0.05) changes in their firing rates to MPH rechallenge at ED10 when
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compared to acute MPH administration, the majority of the CN units, (98/135), exhibiting
increased neuronal activity (Table 4A, under rechallenge; Fig. 8)
3.5.3 CN neuronal based on behavior (10.0mg/kg, Table 4B and 4C)
Table 4B and C summarizes the CN unit responding to 10.0mg/kg based on their
behavioral responses to chronic MPH. The natural log odds ratio shows that for
10.0m/kg the animals expressing behavioral sensitization were more likely, (ln 3, ln 1.7)
to show an increase in neuronal activity during initial (acute) MPH exposure and at ED10
baseline compared to ED1 baseline. MPH rechallenge at ED10 administration showed
that the behaviorally tolerant animals were more likely to show an increase in activity ln
0.32. Furthermore when the CN neuronal population of those exhibiting behavioral
tolerance was compared to the neuronal activity of those exhibiting behavioral
sensitization a significant [df 2: x2:13.19; p=0.001) difference was observed. Accordingly,
proving our hypothesis that there are intrinsic differences in responses to MPH exposure
that lead to different behavioral responses.
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Figure 7: 7A top histogram summarizes the overall (N=12) behavioral response to acute
and chronic 10.0mg/kg MPH. The bottom histogram separates the animals based on
their individual response of either behaviorally sensitized (N=2) (left 7B) or behaviorally
tolerant (N=10)(right 7C). * represents significant (p<0.05) differences. ED =
experimental day; v= compared to; BL =baseline activity; MPH = methylphenidate.
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Table 4:

All animals
A) 10.0mg/kg total
(N=135)

Animals Exhibiting
Behavioral
Sensitization

Animals Exhibiting
Behavioral
tolerance

B) 10.0mg/kg (N=22)

C) 10.0mg/kg (N=113)

Acute
ED1

Baseline
(ED10 to
ED1)

Rechallenge
(ED10)

Acute ED1

Baseline
(ED10 to
ED1)

Rechallenge
(ED10)

Acute ED1

Baseline
(ED10 to
ED1)

Rechallenge
(ED10)

increase ↑

90

34

98

22

15

21

68

19

77

decrease ↓

31

101

37

0

12

10

31

89

27

No change
≠
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0

0

0

0

0

14

0

0

34

75
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Figure 8: The figure shows a representative histogram of CN unit firing rate following
saline and MPH (10.0 mg/kg) at experimental day 1 (ED1) and ED10. In the left side are
the recordings of ED1 following saline and by MPH 10.0 mg/kg acute injection.
injection The drug
elicited an increase in neuronal firing rates. In the right part of the figure is the histogram
of the baseline activity and the activity following 10.0 mg/kg MPH at ED10. The
histogram shows that at ED10 the baseline activity was evaluated comp
compared
ared to ED1
baseline and following rechallenge of 10.0 mg/kg MPH exposure a further increase in
firing patterns were observed compared to the activity obtained at ED1. This further
increase in neuronal firing rate at ED10 can be interpreted as the unit is expressing
neurophysiological sensitization.
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5 Statistical comparisons
5.1 CN units based on behavior (0.6, 2.5 and 10.0mg/kg MPH) controlling for dose
Based on the separations of the neuronal activity for the animals behavioral
response of either tolerant or sensitized, a log linear model was used to statistical
compare the relationship between dose, behavior and firing patterns for each group (0.6,
2.5 and 10.0 mg/kg MPH) with significance set at (P<0.05). The results shows that the
response pattern of CN units recorded from animals that exhibited behavioral
sensitization to 0.6 mg/kg MPH dose were not significantly (df 2; X2 :3.08; p = 0.2)
different from the CN units firing patterns recorded from animals that exhibited
behavioral tolerance. The response of CN units to MPH recorded from animals that
exhibited behavioral sensitization following 2.5 and 10.0 mg/kg MPH were significantly
(df 2: X2 :30.41; p = 0.001; df 2: X2 :13.19; p = 0.001 ) different from the CN units which
were recorded from animals exhibiting behavioral sensitization. This statistical
comparisons show the importance of evaluating the effect of chronic drug exposure on
neurophysiological events based on animal behavioral response to repetitive drug
exposure.
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6 Discussion
Although MPH is a commonly prescribed drug therapy, its neurochemical mechanism is
still unclear. Several studies have shown that MPH acts similarly to other
psychostimulants, such as cocaine and methamphetamine (Gately et al., 1999, Patrick
and Markowitz, 1997; Teo et al., 2003). Merchant et al., demonstrated that while most
psychostimulants affect both the limbic and basal ganglia circuitry, MPH appears to act
selectively on the basal ganglia circuit, including the caudate nucleus (CN). MPH is
known to indirectly increase synaptic levels of dopamine (DA) by blocking DA re-uptake
into the presynaptic terminal, thereby increasing the levels of extracellular DA in the
synaptic cleft (Diaz et al., 2004; Kuczenski and Segal 1997; Nestler 2001; Volkow et al
1995). In addition to the neurochemical mechanism of MPH being unclear, it is also not
known how MPH might influence behavioral responses, such as sensitization or
tolerance. Previous studies have shown conflicting results as to whether certain doses of
MPH cause behavioral sensitization or behavioral tolerance (Yang et al., 2006). We
have postulated that MPH causes behavioral sensitization in some animals and
behavioral tolerance in others, even when the animals have been administered the same
dose of the drug. This, perhaps, may explain previous findings that yielded conflicting
results. In our studies using electrophysiological methodologies, we demonstrated that
acute and chronic MPH (2.5mg/kg) causes an increase in CN response patterns in some
animals, while decreasing CN response patterns in others (Claussen and Dafny 2012).
However, there are currently no studies that combine the simultaneously recorded
behavioral activities and neuronal responses following MPH administration. We
endeavored to compare behavioral activities to neuronal responses in order to aid in
further understanding their relationship after either acute or chronic MPH exposure. We
investigated this relationship using freely behaving rats as a model, as their behavioral
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and neuronal responses to MPH are similar to those responses observed in humans.
The results obtained from these investigations will aid in better understanding the
mechanism(s) of how acute and chronic MPH exposure may cause behavioral
sensitization or tolerance. We hypothesized that, following chronic MPH exposure, the
CN neuronal population activity from animals exhibiting behavioral sensitization would
respond differently than the CN units recorded from animals exhibiting behavioral
tolerance. The first specific aim of this project was to individually analyze the animals’
behavioral responses to acute and chronic MPH exposure in varying doses (0.6, 2.5 and
10.0mg/kg) to determine if the animals exhibited behavioral sensitization or behavioral
tolerance. The second specific aim involved recording all of the CN neuronal responses
with no relation to the animals’ behavior. Finally, in the third specific aim we sorted the
CN neuronal responses from animals into two groups: 1) those that exhibited behavioral
sensitization and 2) those that exhibited behavioral tolerance. We then determined if
there was a difference between these two groups’ electrophysiological responses. To
accomplish all of these aims, we simultaneously recorded the neuronal and behavioral
activity of animals exposed to single and repetitive doses (0.6, 2.5 and 10.0mg/kg) of
MPH.
Overall, we observed that MPH, in fact, caused behavioral sensitization in some
animals and behavioral tolerance in others, even when these animals were administered
the same dose of the drug. We also demonstrated that there were differences in CN
neuronal responses to acute and chronic MPH exposure that were independent of their
behavioral responses. Finally, we observed that these different responses were
statistically significant in regard to the CN activity between animals that exhibited
behavioral sensitization and those that exhibited behavioral tolerance when administered
specific doses of MPH. Taken together, the results from this study support our

38

hypothesis that the behavioral responses following acute and chronic MPH exposure are
related to neuronal activity in the CN.
Behavioral Responses to Varying Doses of MPH
Previous experiments have reported that both behavioral sensitization
and tolerance can occur when an animal is given the same dose of MPH (Yang et al.,
2006a; Yang et al., 2006b). Therefore, we investigated the behavioral responses,
measured as locomotor activity, in all animals, initially as a group, and then individually
to determine if individual responses were observed using the same dose of MPH. The
saline control group showed no changes in locomotor activity. This suggests that animal
handling for the duration of the study had no significant effects on their behavioral
responses. We next investigated how acute exposure to MPH altered behavioral
responses. Animals that were acutely exposed to MPH exhibited an increase in
locomotor activity in a dose-dependent manner. We also examined how MPH elicited a
chronic effect by re-challenging the animals at a later time after cessation of acute
exposure. The behavioral responses observed on re-challenge were then compared to
responses recorded during the first day of initial acute exposure to MPH. This
comparison was performed for each dose of MPH (0.6, 2.5, and 10mg/kg) that was
administered. Interestingly, upon re-challenge, some animals exhibited decreased
locomotor activity, while others exhibited greatly increased locomotor activity. While
there was a dichotomy in behavioral responses upon re-challenge, there were no
significant differences in the combined locomotor activity for all of the animals rechallenged with MPH, as there was a cancelling out effect during statistical analyses.
Based on this observation, animals were subsequently analyzed individually and then
separated into two groups: behaviorally sensitized and behaviorally tolerant. When the
animals were separated based on their behavioral responses, the animals exhibiting
behavioral tolerance to chronic MPH showed both a larger and a dose-dependent
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increase in response to the initial (acute) MPH exposure when compared to the
behaviorally sensitized animals’ responses (Fig. 3B&C, 5B&C, 7B&C). This was true for
all doses administered. The opposite was seen following MPH re-challenge; the
sensitized groups showed significant increases in locomotor activity upon re-challenge
compared to their initial response, and the tolerant group showed significantly decreased
locomotor activity. In conclusion, it is evident that MPH can elicit either behavioral
sensitization or tolerance that is independent of the dose administered and that the
varying levels of behavioral responses following acute MPH exposure may predict
behavioral responses to chronic MPH exposure.
CN Neuronal Responses to Acute MPH Exposure
Saline administration (N=10) did not have an effect on CN neuronal activity,
suggesting that the handling of the animals also had no effect. The 0.6, 2.5 and 10.0
mg/kg MPH exposures altered the majority of CN neuronal activity. Some CN units
responded with increased neuronal activity, while others responded with attenuation of
neuronal responses or were nonresponsive. The CN is comprised of approximately 90%
medium spiny neurons (MSNs); there are two types of MSNs which express two different
DA receptors: D1- and D2-like receptors. The D1 receptors act on the direct output
pathway that connects to the thalamus and other cortical areas by way of the globus
pallidus internal (GPi) and substantia nigra pars reticulars (SNPr) (Hummel & Unterwald,
2002). Acute MPH administration is believed to stimulate C-Fos mRNA expression in the
direct pathway, which increases D1 receptor-mediated signal transduction and causes
an overall excitatory response for all doses (Yano and Steiner 2005; Chase et al., 2005).
Therefore, D1 receptors have an excitatory effect when activated. The indirect pathway
is regulated by D2 receptors with connections that project to the globus pallidus external
(GPe), which then project to the subthalamic nucleus and causes an overall inhibition of
activity (Henry & White, 1995). Extracellular recordings from permanent electrodes
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previously implanted into the CN are not able to identify the exact origin of the
recordings or whether they are comprised of neurons expressing a majority of D1 or D2
DA receptors. Therefore, it has been postulated that when excitatory responses are
observed, across all doses, that this is due to D1 receptor activity; whereas, when
inhibitory responses are observed, D2 receptors are involved. It is known that the MSN
are usually quiet and do not exhibit any spontaneous activity, therefore, when no
response is observed, it may be because of a week stimulus that is unable to activate
the cell.
CN Neuronal Responses to Chronic MPH Exposure
The saline control group showed no changes in neuronal firing patterns at
experiment al 10 (ED10) when compared to their activity at ED1, confirming that
handling of the animals and multiple injections had no effect on the CN neuronal
responses. When the CN units were exposed to a rechallenge (chronic) MPH, following
6 days of administration and 3 days washout, we observed three types of
neurophysiological sensitization and three types of neurophysiological tolerance.
Neurophysiological sensitization was considered if the neuronal population at ED1 was
increased compared to the ED1 baseline neuronal responses and then a further
increase at ED10 compared to ED1 neuronal activity or similarly a decrease at ED1 and
ED10, also when no changes were observed at ED1 drug compared to ED1 baseline
neuronal activity followed by an increase at ED10 drug rechallenge when compared to
ED1 drug neuronal responses. Neurophysiological tolerance was observed when
neuronal responses at ED1 were increased following acute drug exposure followed by a
decrease in neuronal firing rates at ED10 drug compared to ED1 drug or oppositely a
decreased followed by increase, also when there were no response at ED1 drug
however a decrease in neuronal firing was at ED10 compared to ED1 drug was
observed. When the CN neuronal responses were analyzed independently of the
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animals’ locomotor behavior, the CN units responded initially to 0.6mg/kg MPH, with a
majority showing an increase at ED1. However, at ED10, the majority of the CN
neuronal responses elicited an opposite response by exhibiting a decrease in neuronal
activity. An increase in neuronal activity following initial MPH exposure and then a
decrease following chronic MPH exposure can be interpreted as neurophysiological
tolerance. The 2.5 and 10.0 mg/kg MPH exposures elicited increases in CN neuronal
activity and revealed an overall greater rise in activity at ED10 following re-challenge
with MPH compared to their acute response at ED1. This increase in CN neuronal
activity at ED1 followed by a further increase at ED10 re-challenge with MPH can be
interpreted as neurophysiological sensitization. There were also CN units that exhibited
a decrease in neuronal activity at ED1 followed by a further decrease in neuronal firing
rates, thereby exhibiting neurophysiological sensitization. There were some units for all
doses (0.6, 2.5 and 10.0mg/kg) that did not respond following initial MPH exposure but
did elicit an increase in activity at ED10 re-challenge. Therefore, these CN units
exhibited neurophysiological sensitization. Some CN units responded to initial MPH
exposure at ED1 but were nonresponsive at ED10 re-challenge. These CN units were
classified as expressing neurophysiological tolerance. Based on these experiments it is
clear that there are different responses occurring at different days and across different
doses. Therefore, as hypothesized we further separated the animals based on their
behavioral response and compared the CN neuronal activity. First, however, I will
attempt to explain the reasons for why there are differing results across doses and days.
Nikolaus et al. (2011) used in vivo experiments to measure the level of D2
inhibitory receptors in the striatum of both baboons and rats and reported that there was
a decrease in the amount of D2 receptors when animals were exposed to increasing
doses of MPH. Also, chronic MPH exposure has been shown to increase the number of
∆FosB positive MSN D1, ∆FosB is a transcription factor that is shown to increase in
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concentration on the medium spiny neurons (MSN) that express D1 like Dopamine (DA)
receptors (Nikolaus et al., 2011). The above reports could explain why the majority of
CN units exhibited increased firing rates at ED10 when exposed to 10.0 mg/kg of MPH.
For those animals administered 0.6 mg/kg of MPH, we found that the majority of CN
units demonstrated either no change in activity or a decrease in neuronal activity, which
contradicts what was found in previous studies. This type of activity may result from
more D2 receptor availability, which would mediate inhibition.
The phenomenon of sensitization can be examined by looking at gene
expression and neuropeptides levels (Alburges et al., 2011; Brandon and Steiner, 2003;
Nikolaus et al., 2011; Yano and Steiner, 2005). The differential behavioral and neuronal
responses following MPH exposure that we observed in this study may be explained by
two possible mechanisms. One of these possible mechanisms is that chronic MPH
ultimately increases the expression of ∆FosB leading to sensitization. The striatum is
believed to be involved in psychostimulant induced gene regulation due to
overstimulation of DA receptors (Yano and Steiner 2005). It has been demonstrated in
some animals that chronic exposure to psychostimulants results in an increase in the
density of dendrite spines in MSNs that express D1 DA receptors (Kim et al., 2009) as
well as the transcription factor ∆FosB (Robison and Nestler, 2011). Psychostimulant
induced overexpression of ∆FosB has been linked to the exhibition of a sensitized state
in animal models (Kim et al., 2009).It has also been shown that repetitive exposure to
psychostimulants results in super sensitivity of D1-like DA receptors in the nucleus
accumbens (NAc), which leads to the expression of the sensitized response (Wolf, 2002;
Wolf et al., 2003; 2004). This increase in the upregulation of ∆FosB, which causes units
to express a sensitized state, explains the results of our current study. We found that
when animals were exposed to either 2.5 or 10.0 mg/kg of MPH, the majority of CN
neuronal units showed a greater increase in firing rates and therefore exhibit
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neurophysiological sensitization. ∆FosB is generated by alternative splicing and lacks
the two degron domains present in the full-length protein (Kelz et al., 1999). Without
these two domains, previous studies have shown there is a four-fold increase in protein
stability (Robinson and Nestler, 2011). In addition, using both in vitro and in vivo
methodologies, studies have demonstrated that ∆FosB is phosphorylated, which further
stabilizes the protein by approximately ten-fold (Kelz et al., 1999). This intrinsic protein
stability provides a molecular mechanism by which psychostimulant changes in gene
expression can persist long after the administration of MPH is ceased (Robinson and
Nestler 2011). Another possible mechanism to explain the results of this study is that the
alterations in the neuronal activity that we observed may be due to the structural
plasticity of the neurophil (soma and dendrite spine morphology) in the brain reward
circuitry as a result of repetitive MPH exposure (Dietz et al., 2009; Robinson and Kolb,
2004; Russo et al., 2010). Increased activation of D1-like DA receptors and increases in
neurophil density may also result in neurophysiological sensitization. Further studies are
needed to be performed to further dissect which mechanisms may be involved in MPH
modulation of behavioral responses.
Previously, it has been shown that overexpression of cAMP- responsive element
binding protein (CREB) occurs both in the D1 and D2-like DA receptors and decreases
the rewarding effects of psychostimulants, thereby causing neurophysiological tolerance
(Robinson and Nestler, 2011). Activation of D2-like DA receptors and decreases in
neurophil density result in attenuated MPH-mediated effects that can be explained as
neurophysiological tolerance. Moreover, Madsen et al. (2012) reported that mice
deficient in striatal CREB1, a transcription factor that is known to initiate downstream
genes and is specific to MSNs of the dorsal striatum and CREB-binding protein (CBP)-,
created a heightened sensitivity to psychostimulants by causing a prolonged to them.
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Comparison of CN neuronal activity in animals exhibiting behavioral sensitization
to those expressing behavioral tolerance after chronic MPH exposure
The CN neuronal responses recorded following MPH exposure were evaluated
based on the animals’ behavioral responses to chronic MPH administration. Animals
were then classified based on their behavioral response and grouped as either
behaviorally sensitized or behaviorally tolerant. Finally, their neuronal activity was
evaluated based on their separate behavioral responses. First, we applied statistical
analyses to CN neuronal activities recorded from animals exhibiting behavioral
sensitization and those exhibiting behavioral tolerance to determine if a significant
difference was found in their responses to acute and chronic MPH .These statistical
analyses were also performed to compare groups that were acutely and chronically
exposed to MPH.
In the group of animals exposed to 0.6 mg/kg of MPH, there were no significant
differences in the neuronal responses for those exhibiting behavioral sensitization
compared to those exhibiting behavioral tolerance. Furthermore, when investigating
neuronal responses to better understand behavioral responses, no significant
correlations were observed. This is explained by the fact that the CN is a motor circuit,
and 0.6 mg/kg of MPH is considered a low dose that does not modify the motor
responses; therefore, this response was expected.
Significant differences were found in CN neuronal populations exposed to 2.5
mg/kg of MPH when results were separated based on the animals’ behavioral response
of either sensitization or tolerance. The CN neuronal responses to acute 2.5 mg/kg MPH
exposure in animals exhibiting behavioral sensitization showed a combination of
increases and decreases in neuronal activity, whereas the majority of those animals that
exhibited behavioral tolerance showed an increase in their neuronal responses. This
may be explained by the fact that the tolerant animals showed a heightened behavioral
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response (Table 3C, Fig. 5C) to the initial (acute) drug exposure compared to sensitized
animals (Table 3B, Fig. 5B). This same correlation phenomenon was seen when
animals were re-challenged with 2.5 mg/kg MPH at day 10 after the initial administration
of MPH had ceased. The behaviorally sensitized animals that were re-challenged with
MPH exhibited more CN units that increased their firing rates, resulting in increased
behavioral responses (Table 3B, Fig. 5B).The behaviorally tolerant animals showed a
significant decrease in their baseline firing rate coupled with a mixture of neuronal
response types (Table 3C, Fig. 5C).
The CN neuronal responses to 10.0 mg/kg MPH were also found to be
statistically different when separated based on the animals’ behavioral responses of
sensitization or tolerance. When comparing the CN neuronal activity to the respective
behavioral responses, similar results were observed as those seen when animals were
administered the 2.5 mg/kg MPH dose. The CN neuronal responses to acute 10.0 mg/kg
MPH, from animals exhibiting behavioral sensitization, exhibited a combination of
increases and decreases, whereas the neuronal responses from the majority of those
exhibiting behavioral tolerance were increased. This could be because the tolerant
animals showed a heightened behavioral response (Table 4C, Fig. 7C) to the initial
(acute) drug exposure compared to the sensitized animals (Table 4B, Fig. 7B), similar to
what was observed at the lower dose of 2.5 mg/kg of MPH. This same correlation
phenomenon was observed when animals were re-challenged at ED10 with 10.0 mg/kg
MPH, as the behaviorally sensitized animals expressed more units that increased their
firing rates, resulting in increased behavioral responses (Table 3B, Fig. 7B). The
behaviorally tolerant animals showed a significant decrease in their baseline firing rates
and a mixture of neuronal responses (Table 3C, Fig. 7C), which, again, is similar to what
was observed when the animals received a lower dose of MPH.

46

In conclusion, experiments in which both neuronal and behavioral responses
were examined using an MPH dose response protocol, it was found that MPH can elicit
different locomotor and neuronal responses to acute and chronic MPH exposures. Also,
as hypothesized, we observed that there is, in fact, a statistically significant difference in
the firing patterns of CN neurons when animals are grouped based on their behavioral
responses to higher doses (2.5 and 10.0 mg/kg) of MPH. Moreover, correlations were
observed when we compared the neuronal responses to the behavioral responses.
Understanding the differences in animals’ reactions to chronic exposure of MPH, in
terms of both the behavioral and neuronal aspects, following chronic MPH exposure is
imperative in future research for analyzing the mechanism by which MPH acts on
neuronal events based on behavioral responses. MPH acts predominately on the DA
receptors, and activation of D1 and D2 DA receptors is known to elicit differing
responses, further studies using specific DA antagonists are needed to investigate their
specific roles in the behavioral and neuronal sensitization/tolerance responses.
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